Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Date Posted: 
2019-06-03
Dr. Chi

The TITAN clinical trial has demonstrated that the addition of apalutamide to androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer. These results were presented by Dr. Kim Chi at ASCO on May 31, and were written up on ASCO Daily News on June 1.  Dr. Chi is first author on the study which was published in the New England Journal of Medicine on May 31.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Tuesday, June 11, 2019

Dr. Cox featured in VCHRI News

Dr. Cox and family
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi